WO1996017861A1 - Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase - Google Patents

Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase Download PDF

Info

Publication number
WO1996017861A1
WO1996017861A1 PCT/US1995/014010 US9514010W WO9617861A1 WO 1996017861 A1 WO1996017861 A1 WO 1996017861A1 US 9514010 W US9514010 W US 9514010W WO 9617861 A1 WO9617861 A1 WO 9617861A1
Authority
WO
WIPO (PCT)
Prior art keywords
obn
trp
tyr
ala
cbz
Prior art date
Application number
PCT/US1995/014010
Other languages
French (fr)
Inventor
Gary Louis Bolton
Alfred Campbell
Richard Gowan
John Cooke Hodges
Donald Hupe
Daniele Leonard
Tomi Sawyer
Judith Sebolt-Leopold
Francis J. Tinney
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US35347394A priority Critical
Priority to US08/353,473 priority
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of WO1996017861A1 publication Critical patent/WO1996017861A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Inhibitors of protein:farnesyl transferase enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling tissue proliferative diseases, including cancer and restenosis.

Description

SUBSTITUTED TETRA- AND PENTAPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE

FIELD OF THE INVENTION

The present invention pertains to a number of compounds which can be used in the medicinal field to treat, prophylactically or otherwise, uncontrolled or abnormal proliferation of human tissues. More specifically, the present invention pertains to a number of compounds which act to inhibit the farnesyl transferase enzyme that has been determined to activate ras proteins which in turn activate cellular division and are implicated in cancer and restenosis.

BACKGROUND OF THE INVENTION

Ras protein (or p21) has been examined extensively because mutant forms are found in 20% of most types of human cancer and greater than 50% of colon and pancreatic carcinomas (J. B. Gibbs, Cell ££, 1 (1991) , T. Cartwright, et al., Chi ica Oσσi 1£, 26 (1992)). These mutant ras proteins are deficient in the capability for feedback regulation that is present in native ras and this deficiency is associated with their oncogenic action since the ability to stimulate normal cell division can not be controlled by the normal endogenous regulatory cofactors. The recent discovery that the transforming activity of mutant ras is critically dependent on posttranslational modifications (J. Gibbs, et al., Mi robiol. Rev. 5J., 171 (1989)) has unveiled an important aspect of ras function and identified novel prospects for cancer therapy.

In addition to cancer, there are other conditions of uncontrolled cellular proliferation that are related to excessive expression and/or function of native ras proteins. Post surgical vascular restenosis is such a condition. The use of various surgical revascularization techniques such as saphenous vein bypass grafting, endarterectomy and transluminal coronary angioplasty is often accompanied by complications due to uncontrolled growth of neointimal tissue, known as restenosis. The biochemical causes of restenosis are poorly understood and numerous growth factors and protooncogenes have been implicated (A. J. Naftilan, et al. , Hypertension 13. 706 (1989) and sL. Clin. Invest. 93. 1419; G. H. Gibbons, et al., Hypertension \ . 358 (1989); T. Satoh, et al. , Mollec. Cell. Biol. 13_, 3706 (1993)). The fact that ras proteins are known to be involved in cell division processes makes them a candidate for intervention in many situations where cells are dividing uncontrollably. In direct analogy to the inhibition of mutant ras related cancer, blockade of ras dependant processes has the potential to reduce or eliminate the inappropriate tissue proliferation associated with restenosis, particularly in those instances where normal ras expression and/or function is exaggerated by growth stimulatory factors. Ras functioning is dependent upon the modification of the proteins in order to associate with the inner face of plasma membranes. Unlike other membrane- associated proteins, ras proteins lack conventional transmembrane or hydrophobic sequences and are initially synthesized in a cytosol soluble form. Ras protein membrane association is triggered by a series of posttranslational processing steps that are signaled by a carboxyl terminal amino acid consensus sequence that is recognized by protein:farnesyl transferase. This consensus sequence consists of a cysteine residue located four amino acids from the carboxyl terminus, followed by two lipophilic amino acids and the C-terminal residue. The sulfhydryl group of the cysteine residue is alkylated by farnesyl pyrophosphate in a reaction that is catalyzed by protein:farnesyl transferase. Following prenylation, the C-terminal three amino acids are cleaved by an endoprotease and the newly exposed alpha-carboxyl group of the prenylated cysteine is methylated by a methyl transferase. The enzymatic processing of ras proteins that begins with farnesylation enables the protein to associate with the cell membrane. Mutational analysis of oncogenic ras proteins indicate that these posttranslational modifications are essential for transforming activity. Replacement of the consensus sequence cysteine residue with other amino acids gives a ras protein that is no longer farnesylated, fails to migrate to the cell membrane and lacks the ability to stimulate cell proliferation (J. F. Hancock, et al., Cell 57. 1617 (1989), W. R. Schafer, et al., Science 215., 379 (1989), P. J. Casey, Proc. Natl. Acad. Sci. USA !£, 8323 (1989) ) .

Recently, protein:farnesyl transferases (PFTs, also referred to as farnesyl:protein transferases) have been identified and a specific PFT from rat brain was purified to homogeneity (Y. Reiss, et al., Bioch. Soc. Trans. 20, 487-88 (1992)). The enzyme was characterized as a heterodimer composed of one alpha- subunit (49 kDa) and one beta-subunit (46 kDa) , both of which are required for catalytic activity. High level expression of mammalian PFT in a baculovirus system and purification of the recombinant enzyme in active form has also been accomplished ( .-J. Chen, et al. , J. Biol. Chem. 268. 9675 (1993)).

In light of the foregoing, the discovery that the function of oncogenic ras proteins is critically dependent on their posttranslational processing provides a means of cancer chemotherapy through inhibition of the processing enzymes. The identification and isolation of a protein:farnesyl transferase that catalyzes the addition of a farnesyl group to ras proteins provides a promising target for such intervention. Recently it has been determined that prototypical inhibitors of PFT can inhibit ras processing and reverse cancerous morphology in tumor cell models (N. E. Kohl, et al., Science 260. 1934 (1993), G. L. James, et al. , Science 260. 1937 (1993), A. M. Garcia, et al. , J. Biol. Chem. 268. 18415 (1993)). Thus, it is possible to prevent or delay the onset of cellular proliferation in cancers that exhibit mutant ras proteins by blocking PFT. By analogous logic, inhibition of PFT would provide a potential means for controlling cellular proliferation associated with restenosis, especially in those cases wherein the expression and/or function of native ras is overstimulated. PCT Application WO91/16340 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula CAAX.

European Patent Application 0461869 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula Cys-Aaa**-Aaa2-Xaa. European Patent Application 0520823 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula Cys-Xaa1-dXaa -Xaa3.

European Patent Application 0523873 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula Cys-Xaa1-Xaa2-Xaa3.

European Patent Application 0528486 discloses cysteine containing tetrapeptide amides inhibitors of PFT of the formula Cys-Xaa1-Xaa2-Xaa3-NRR1. European Patent Application 0535730 discloses pseudotetrapeptide inhibitors of PFT of the following two formulas:

Figure imgf000007_0001

European Patent Application 0535731 (US 5,238,922) discloses esters of pseudotetrapeptide inhibitors of PFT of the formula:

Figure imgf000007_0002

US 4,035,348 discloses tetrapeptide antagonists of luteinizing hormone releasing factor of the formula A-Rj-Tyr(benzyl) -Ser(benzyl) -D-Ala-R2, wherein one of the definitions of R -*-s L-His(benzyl) .

US 4,043,993 discloses pentapeptide antagonists of luteinizing hormone releasing factor of the formula X-R-Tyr(benzyl) -Ser(benzyl) -R1-Y, wherein one of the definitions of R is His(benzyl).

US 4,062,835 discloses pentapeptide antagonists of luteinizing hormone releasing factor of the formula X-R-Tyr(methyl) -Ser(benzyl) -R1-Y, wherein one of the definitions of R is His(benzyl).

Compounds disclosed in the above references do not disclose or suggest a novel combination of structural variations found in the present invention described hereinafter.

SUMMARY OF THE INVENTION

Accordingly, the present invention is a substituted tetra- or pentapeptide compound of Formula I:

Figure imgf000008_0001
wherein n = 1 or 2 ; A = - COR2 , - C02R2 , - CONHR2 , - CSR2 , - C (S ) R2 , - C (S) NHR2 , or H; wherein R2 is alkyl, - (CH2)m-cycloalkyl, - (CH2)m-aryl,

- (CH2)m-heteroaryl, and = 0, 1, 2, or 3;

R = independently H or Me; Y = independently H or Me;

Z = independently H or Me;

Figure imgf000009_0001
wherein R4' * H or Me;

-SR4", wherein R4" - H, alkyl, trityl, or heteroaryl;

Figure imgf000009_0002
wherein R5' - H, -OH, -O-alkyl, alkyl, -CO-aryl,

- (CH2)m-aryl, -0(CH2)m-cycloalkyl, -0(CH2)m-aryl, -0(CH2)m-heteroaryl, -OP03R5"2, -CH2P03R5"2,

-CF2P03RS"2, or -CFHP03R5"2, wherein R5' is located at either the ortho, meta, or para position and R5'' - H, alkyl, alkylaryl, or cyclohexyl, and m is as described above; -COOR7, wherein R7 = H, Me, t-butyl, or benzyl; -SR8, wherein R8 = H or trityl;

R6 = -OR6', wherein R6' = H, benzyl, -P03R5"2, wherein R5'' is as described above; -CH2-R9, wherein R9 = -P03R5''2, wherein R5'' is as described above;

-SR6 ', wherein R6'' ■ H, benzyl, or trityl; C = Gly, Ala, Val, Leu, He, Phe, Tyr, Tyr(OMe) , Pgl, homoPhe, Trp, Trp(Me), or Trp(CHO); D = Gly, Ala, or absent; E = -COOH, -CONH2, -CONHNH2, -CONHR10, or -C02R10, wherein R10 = H, alkyl, - (CH2)m-cycloalkyl,

- (CH2)m-aryl, - (CH2)m-heteroaryl, and m is as described above; an isomer or a pharmaceutically acceptable salt thereof. The present invention is also directed to the use of a compound of Formula I, or a pharmaceutically acceptable salt therefrom, to inhibit the activity of a protein:farnesyl transferase enzyme as a method for treating tissue proliferative diseases. A further embodiment of the present invention is the use of a pharmaceutical composition including an effective amount of a compound of Formula I as a method for the treatment of cancer.

A still further embodiment of the present invention is the use of a pharmaceutical composition including an effective amount of a compound of

Formula I as a method for the treatment of restenosis.

A still further embodiment of the present invention is a pharmaceutical composition for administering an effective amount of a compound of Formula I in unit dosage form in the treatment methods mentioned above.

A final embodiment of the present invention pertains to methods for the preparation of compounds of Formula I by solid phase synthesis and solution phase synthesis.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the compounds of Formula I, the term "alkyl" means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like. The term "cycloalkyl" means a saturated hydrocarbon ring which contains from 3 to 10 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, and the like.

The term "aryl" means an aromatic ring which is a phenyl, 5-fluorenyl, l-naphthyl or 2-naphthyl group, unsubstituted or substituted by l to 3 substituents selected from alkyl, 0-alkyl and S-alkyl, -OH, -SH, -F, -Cl, -Br, -I, -CF3, -N02, -NH2, -NHCH3, -N(CH3)2, -NHCO-alkyl, - (CH2)mC02H, - (CH2)mC02-alkyl, - (CH2)mS03H, - (CH2)mP03H2# - (CH2)mP03 (alkyl)2, - (CH2)mS02NH2, and - (CH2)InS02NH-alkyl wherein alkyl is defined as above and m - 0, 1, 2, or 3.

The term "alkylaryl" means alkyl as defined above and aryl as defined above, for example, benzyl. The term "heteroaryl" means a heteroaromatic ring which is a 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl group, substituted or unsubstituted by 1 or 2 substituents from the group of substituents described above for aryl.

The following table provides a list of abbreviations and definitions thereof used in the present invention.

TABLE OF ABBREVIATIONS

Abbreviation* Amino Acid

Ala Alanine Arg Arginine

Asn Asparagine

Asp Aspartic acid

Cys Cysteine

Glu Glutamic acid Gin Glutamine

Gly Glycine

His Histidine

He Isoleucine

Leu Leucine Lys Lysine

Met Methionine

Phe Phenylalanine

Pro Proline

Ser Serine Thr Threonine

Trp Tryptophan

Tyr Tyrosine

Val Valine

Abbreviation* Modified and Unusual Amino Acid Aaa-C02R An amino acid ester, for examples Gly-C02Me is Glycine, methyl ester; D-Ala-C02Me is D-Alanine, methyl ester.

If the optical activity of the amino acid is other than L(S) , the amino acid or abbreviation is preceded by the appropriate configuration D(R) or DL(RS) . Abbreviation* Modified and Unusual Amino Arid (continued) Aaa-CONHR An amino acid amide, for examples: D-Ala-CONHEt is D-Alanine, N-ethyl amide; Trp-CONH2 is Tryptophanamide.

3Hyp 3-Hydroxyproline

4Hyp 4-Hydroxyproline

Hey Homocysteine

Nva Norvaline

Nle Norleucine

Orn Ornithine

Bal Beta-alanine (or 3-aminopropionic acid)

Abu 4-Aminob tyric acid Ahe 7-Aminoheptanoic acid Acp 6-Aminocaproic acid Aoc 8-Aminooctanoic acid Apn 5-Aminopentanoic acid Bpa (4-Benzoylphenyl)alanine Chx 3-Cyclohexylalanine (or

Hexahydrophenylalanine)

Cit Citrulline His(l-Me) 1-Methyl-histidine (or N(τ) -Methyl- histidine)

His(Tr) 1-Triphenylmethyl-histidine (or

N(τ) -Trityl-histidine) homoPhe 2-Amino-4-phenylbutanoic acid (or

Homophenylalanine) homoTyr 2-Amino-4- (4-hydroxyphenyl)butanoic acid (or Homotyrosine)

If the optical activity of the amino acid is other than L(S), the amino acid or abbreviation is preceded by the appropriate configuration D(R) or D (RS) . Abbreviation Modified and Unusual Amino Acid (continued) homoTyr(OBn) 2-Amino-4- [4- (phenylmethoxy)phenyl] - butanoic acid (or 0-Benzyl- homotyrosine) l-Nal 3- (1' -Naphthyl)alanine

2-Nal 3- (2' -Naphthyl)alanine

Pen Penicillamine

Phe(3-OBn) (3-Benzyloxyphenyl)alanine

Phe(4-Ph) 3- (1,l'Biphen-4-yl)alanine (or

4-Phenyl-phenylalanine)

Pgl Phenylglycine

Pyr 2-Amino-3- (3-pyridyl) -propanoic acid

(or 3-Pyridylalanine)

Ser(OBn) 0-Benzyl-serine

Thr(OBn) 0-Benzyl-threonine

Tic 1,2,3,4-Tetrahydro-3-isoquinoline- carboxylic acid

Tyr(OMe) 0-Methyl-tyrosine

Tyr(OEt) 0-Ethyl-tyrosine

Tyr(OBn) 0-Benzyl-tyrosine

(α-Me)Tyr(OBn) 2-Amino-3- (4-benzyloxyphenyl) -

2-methyl-propionic acid (or α-Methyl-0-benzyl-tyrosine) (N-Me)Tyr(OBn) N-Methyl-0-benzyl-tyrosine Trp(For) Nin-Formyltryptophan

Abbreviation Mercapto Acids

Maa Mercaptoacetic acid

Mba 4-Mercaptobutyric acid

Mpa 3-Mercaptopropionic acid

If the optical activity of the amino acid is other than L(S) , the amino acid or abbreviation is preceded by the appropriate configuration D'R) or DL(RS) . Abbreviation Protectinσ Group

Ac Acetyl

Ada 1-Adamantyl acetic acid

Adoc Adamantyloxycarbonyl

Bn Benzyl

MeBn 4-Methylbenzyl

Cbz Benzyloxycarbonyl

2-Br-Cbz ortho-Bromobenzyloxycarbonyl

2-Cl-Cbz ortho-Chiorobenzyloxycarbonyl

Bom Benzyloxymethyl

Boc tertiary Butyloxycarbonyl

Dnp 2,4-Dinitrophenyl

For For yl

Fmoc 9-Fluorenylmethyloxycarbonyl

N02 Nitro

Tos 4-Toluenesulfonyl (tosyl)

Tr Triphenylmethyl (trityl)

Abbreviation Solvents and Reaσents HOAc Acetic acid

CF3S02H Trifluoromethanesulfonic acid

DCM Dichloromethane

DCC N,N' -Dicyclohexylcarbodiimide

DIC N,N' -Diisopropylcarbodiimide DIEA N,N-Diisopropylethylamine

DMAP 4-Dimethylaminopyridine

DMF N,N' -Dimethylformamide

EDAC N-Ethyl-N' -Dimethylaminopropylcarbo- diimide EtOAc Ethyl acetate

Et20 Diethyl ether

HCl Hydrochloric acid

HF Hydrofluoric acid

HOBT 1-Hydroxybenzotriazole KOH Potassium hydroxide

MeCN Acetonitrile Abbreviation Solvents and Reagents (continued)

MeOH Methanol

NHOS N-Hydroxysuccinimide

NMP N-Methylpyrrolidone iPrOH iso-Propanol

TFA Trifluoroacetic acid

Abbreviation Solid Phase Peptide Svnthesis Resins HMP Resin 4- (Hydroxymethyl) -phenoxymethyl-poly styrene resin

MBHA Resin Methylbenzhydrylamine resin PAM Resin 4- (Hydroxymethyl) - phenylacetamidomethy1-polystyrene resin

2-Cl-Tr Resin 2-Chlorotrityl-polystyrene resin NH2-Rink Resin 4- (amino- (2' ,4' -dimethoxyphenyl) - methyl) -phenoxymethyl-polystyrene resin

Abbreviation Biological Reaσents

FPP Farnesyl pyrophosphate

PFT Protein:farnesyl transferase

DTT Dithiothreitol

BSA Bovine serum albumin

Abbreviation Miscellaneous COR2 0

-C ■R 22

Figure imgf000016_0001

CONHR**

Figure imgf000016_0002

CSR" S

-C IR 22 Abbreviation Miscellaneous (continued)

Figure imgf000017_0001

C(S)NHR2 S

-C llNHR 2 2

CONH2 0 -C IINH2

C0NHNH2 0 -C IINHNH2

CONHR2 0

-C llNHR2 2

Preferred compounds of the invention are designated by Formula II:

Figure imgf000017_0002
wherein n' = 1 or 2;

A' = -COR2', -C02R2', or -CONHR2', wherein R2' = alkyl, - (CH2)m-aryl, - (CH2)m- heteroaryl, and m = 0, 1, or 2; R = independently H or Me; Y = independently H or Me;

Z = independently H or Me;

R12'

Figure imgf000017_0003
or Me; ■SR12", wherein R12" - H or alkyl;

Figure imgf000018_0001
wherein R13' - H, -OH, -O-alkyl, alkyl, -CO-aryl, benzyl, -O-benzyl, wherein R13' is located at either the ortho, meta, or para position;

-OP03R1 2, -CH2P03R1 2, or -CF2P03R1 2, wherein R14 - H or alkyl; -COOR15, wherein R15 » H, Me, t-butyl, or benzyl;

R16 = -OR16', wherein R16' = H, benzyl, -P03R1 2, wherein R14 is as described above;

-CH2-R16", wherein R16" - -P03R14 2, wherein R14 is as described above; -SR16'", wherein R16'" = H or benzyl;

C = Ala, Trp, Trp(Me), or Trp(CHO);

D' = Gly, Ala, or absent;

E' = -COOMe, -CONH2, -CONHNH2, -COOH or -CONH-alkyl; an isomer or a pharmaceutically acceptable salt thereof. Other preferred compounds of the present invention are those of Formula I as defined above wherein A is

Cbz, BnNHCO, R is H and n is 1 or 2; or as defined above wherein R4 is

Figure imgf000018_0002

or as defined above wherein wherein R5 is

Figure imgf000018_0003
wherein R5' is H, -OH, -OBn, -OP03H2, -CH2P03H2, -CH2P03Et2, -CF2P03H2, or wherein R5 = -COOH, and Z is H; or as defined above wherein R6 is -OBn, -OH, -SH, or -OP03H2; or as defined above wherein C is Trp or Ala; or as defined above wherein D is Ala, Gly, or absent; or as defined above wherein E is -COOH, -C0NH2, -COOMe, -CONHEt, -CONHNH2, or -CONHMe.

Most preferred compounds of the invention include the following:

Cbz -His -Tyr (OBn -Ser(OBn) -Trp-D-Ala-CONH2; Cbz - His -Tyr (OBn -Ser(OBn) -Trp-D-Ala-CONHMe; Cbz -His - Tyr (OBn -Ser(OBn) -Trp-D-Ala-CONHEt; Cbz -His -Tyr (OBn -Ser(OBn) -Trp-D-Ala-CONHNH2; CCbbzz- -HHiiss- -TTyyrr((OOBBnn) -Ser(OBn) -Trp-D-Ala-C02Me; Cbz His • Tyr (OBn -Ser(OBn) -Trp-D-Ala; Cbz - His Tyr (OBn -Ser(OBn) -Trp-Ala-CONH2; Cbz -His Tyr (OBn -Ser(OBn) -Trp-Ala-CONHMe; Cbz - His Tyr (OBn -Ser(OBn) -Trp-Ala-CONHE ; Cbz - His Tyr (OBn -Ser(OBn) -Trp-Ala-CONHNH2; Cbz - His Tyr (OBn -Ser(OBn) -Trp-Ala-C02Me; Cbz - His • Tyr (OBn -Ser(OBn) -Trp-Ala; Cbz - His Tyr (OBn -Ser(OBn) -Trp-Gly-CONH2; Cbz His Tyr (OBn -Ser(OBn) -Trp-Gly-CONHMe; Cbz His Tyr (OBn -Ser(OBn) -Trp-Gly-CONHEt; Cbz His Tyr ( OBn -Ser(OBn) -Trp-Gly-CONHNH2; Cbz •His Tyr (OBn -Ser(OBn) -Trp-Gly-C02Me; Cbz •His • Tyr (OBn -Ser(OBn) -Trp-Gly; Cbz •His •Tyr- Ser [OBn) -Trp-D-Ala-CONH2; CCbbzz-HHiiss- TTyyrr((OOBBnn) -Ser-Trp-D-Ala-CONH2; Cbz His Phe - Ser (OBn) -Trp-D-Ala-CONH2; Cbz His Phe - Ser(OBn) -Trp-Ala-CONH2; Cbz His Tyr ( OBn -Ser(OBn) -Ala-D-Ala-CONH2; Cbz-D-His-Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH2; Cbz-His-D-Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH2;

Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-C02Me; Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-CONH2; Cbz-His-Tyr(OBn) -Ser(OBn) -D-Ala-C02Me; Cbz-His-Tyr(OBn) -Ser(OBn) -D-Ala; Cbz-D-His-Tyr(OBn) -Ser(OBn) -Trp-C02Me;

Cbz-His-D-Tyr(OBn) -Ser(OBn) -Trp-C02Me; Cbz-His-Tyr (OBn) -Cys-Trp-CONH2;

BnNHCO-His-Tyr(OBn -Cys-Trp-CONH2; BnNHCO-His-Tyr(OBn -Ser(OBn -Trp-D-Ala-CONH2; BnNHCO-His-Tyr (OBn -Ser (OBn -Trp-D-Al -CONHMe;; BnNHCO-His-Tyr (OBn -Ser (OBn -Trp-D-Ala-CONHEt; BnNHCO-His-Tyr (OBn -Ser(OBn -Trp-D-Ala-CONHNH2; BnNHCO-His-Tyr(OBn -Ser(OBn -Trp-D-Ala-C02Me; BnNHCO-His-Tyr (OBn -Ser(OBn -Trp-D-Ala; BnNHCO-His-Tyr (OBn -Ser (OBn -Trp-Ala-CONH2; BnNHCO-His-Tyr(OBn -Ser(OBn -Trp-Ala-CONHMe; BnNHCO-His-Tyr{OBn -Ser(OBn -Trp-Ala-CONHEt; BnNHCO-His-Tyr(OBn -Ser(OBn -Trp-Ala-CONHNH2; BnNHCO-His-Tyr(OBn -Ser(OB -Trp-Ala-C02Me; BnNHCO-His-Tyr(OBn -Ser(OBn -Trp-Ala; BnNHCO-His-Tyr(OBn -Ser(OBn -Trp-Gly-CONH2; BnNHCO-His-Tyr (OBn -Ser(OBn -Trp-Gly-CONHMe; BnNHCO-His-Tyr (OBn -Ser(OBn -Trp-Gly-CONHEt; BnNHCO-His-Tyr(OBn -Ser(OBn -Trp-Gly-CONHNH2; BnNHCO-His-Tyr(OBn -Ser (OBn -Trp-Gly-C02Me; BnNHCO-His-Tyr (OBn -Ser(OBn -Trp-Gly; Cbz-His-Tyr (OBn -Cys-Trp-D-Ala-CONH2; Cbz-His-Tyr (OBn -Cys-Trp-D-Ala-CONHMe; Cbz-His-Tyr(OBn -Cys-Trp-D-Ala-CONHEt; Cbz-His-Tyr (OBn -Cys-Trp-D-Ala-CONHNH2,* Cbz-His-Tyr (OBn -Cys-Trp-D-Ala-C02Me; Cbz-His-Tyr(OBn -Cys-Trp-D-Ala; Cbz-His-Tyr(OBn -Cys-Trp-Ala-CONH2; Cbz-His-Tyr(OBn -Cys-Trp-Ala-CONHMe; Cbz-His-Tyr(OBn -Cys-Trp-Ala-CONHEt; Cbz-His-Tyr (OBn -Cys-Trp-Ala-CONHNH2; Cbz-His-Tyr(OBn -Cys-Trp-Ala-C02Me; Cbz-His-Tyr (OBn -Cys-Trp-Ala; Cbz-His-Tyr (OBn -Cys-Trp-Gly-CONH2; Cbz-His-Tyr (OBn -Cys-Trp-Gly-CONHMe; Cbz-His-Tyr (OBn -Cys-Trp-Gly-CONHEt; Cbz-His-Tyr (OBn -Cys-Trp-Gly-CONHNH2; Cbz-His-Tyr(OBn) -Cys-Trp-Gly-C02Me;

Cbz-His-Tyr(OBn) -Cys-Trp-Gly;

BnNHCO-His-Tyr(OBn) -Cys-Trp-D-Ala-CONH2;

BnNHCO-His-Tyr(OBn) -Cys-Trp-D-Ala-CONHMe; BnNHCO-His-Tyr(OBn) -Cys-Trp-D-Ala-CONHEt;

BnNHCO-His-Tyr(OBn) -Cys-Trp-D-Ala-CONHNH2;

BnNHCO-His-Tyr(OBn) -Cys-Trp-D-Ala-C02Me;

BnNHCO-His-Tyr(OBn) -Cys-Trp-D-Ala;

BnNHCO-His-Tyr(OBn) -Cys-Trp-Ala-CONH2; BnNHCO-His-Tyr(OBn) -Cys-Trp-Ala-CONHMe,•

BnNHCO-His-Tyr(OBn) -Cys-Trp-Ala-CONHEt;

BnNHCO-His-Tyr(OBn) -Cys-Trp-Ala-CONHNH2;

BnNHCO-His-Tyr(OBn) -Cys-Trp-Ala-C02Me;

BnNHCO-His-Tyr(OBn) -Cys-Trp-Ala; BnNHCO-His-Tyr(OBn) -Cys-Trp-Gly-CONH2;

BnNHCO-His-Tyr(OBn) -Cys-Trp-Gly-CONHMe;

BnNHCO-His-Tyr(OBn) -Cys-Trp-Gly-CONHEt;

BnNHCO-His-Tyr(OBn) -Cys-Trp-Gly-CONHNH2;

BnNHCO-His-Tyr(OBn) -Cys-Trp-Gly-C02Me; BnNHCO-His-Tyr(OBn) -Cys-Trp-Gly;

Cbz-Cys-Tyr(OBn) -Ser(OBn) -Trp-DAla-CONH2;

Cbz-His-Tyr(OP03H2) -Ser(OBn) -Trp-DAla-CONH2;

Cbz-His-p(CH2P03H2)Phe-Ser(OBn) -Trp-DAla-CONH2;

Cbz-His-p(CH2P03Et2)Phe-Ser(OBn) -Trp-DAla-CONH2; Cbz-His-p(CF2P03H2)Phe-Ser(OBn) -Trp-DAla-CONH2;

Cbz-His-Glu-Ser(OBn) -Trp-DAla-CONH2;

Cbz-His-Asp-Ser(OBn) -Trp-DAla-CONH2;

Cbz-His-Tyr(OBn) -Ser(OP03H2) -Trp-DAl -CONH2;

Cbz-His-Tyr(OP03H2) -Cys-Trp-DAla-CONH2; and Cbz-His-Tyr(OP03H2) -Ser(OBn) -Trp-CONH2. GENERAL METHODS FOR THE PREPARATION, EVALUATION AND USE OF COMPOUNDS OF FORMULA I

The compounds of Formula I may be prepared by solid phase peptide synthesis on a peptide synthesizer, for example, an Applied Biosystems 430A peptide synthesizer using activated esters or anhydrides of Boc or Fmoc protected amino acids, acid chlorides, isocyanates, isothiocyanates, etc, on PAM, MBHA, or NH2-Rink resins with solution phase modifications to the carboxyl terminus as appropriate. Methodology for the solid phase synthesis of peptides is widely known to those skilled in the art thereof (see, for example: J. M. Stewart and J. D. Young in Solid Phase Peptide Synthesis: Pierce Chemical Co.; Rockford, IL (1984); G. B. Fields and R. L. Noble, Int. J. Peptide Protein Res. 35. 161-214 (1990)). Additionally, the compounds of Formula I may also be prepared by conventional solution peptide synthesis, substituting amines, acid chlorides, isocyanates, etc, for amino acid derivatives where appropriate. Methods for solution phase synthesis of peptides are widely known to those skilled in the art (see, for example, M. Bodanszky, Principles of Peptide Svnthesis. Springer-Verlag (1984)). For both of the synthetic methods described above appropriate consideration is given to protection and deprotection of reactive functional groups and to the sequence of synthetic steps. Knowledge of the use of common protecting groups and strategy for the assembly of complex organic molecules are within the usual realm of expertise of a practitioner of the art of organic chemistry (see, for example: T. W. Greene and P. G. M Wuts, Protective Groups in Organic Chemistry. John Wiley and Sons (1991); E. J. Corey and X.-M. Cheng, The Logic of Chemical Synthesis. John Wiley and Sons (1989) ) . The homogeneity and composition of the resulting compounds is verified by RP-HPLC, capillary electrophoresis, thin layer chromatography (TLC), proton nuclear magnetic resonance spectrometry (NMR) , amino acid analysis, chemical ionization mass spectrometry (CI-MS) , fast atom bombardment mass spectrometry (FAB-MS) and electrospray mass spectrometry (ES-MS) .

The compounds of Formula I are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present invention.

Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glucamine (see, for example, S. M. Berge, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Ssi≤nC≤ ££, 1-19 (1977)).

The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. Preferably a compound of Formula I can be converted to an acidic salt by treating with an aqueous solution of the desired acid, such that the resulting pH is less than 4. The solution can be passed through a C18 cartridge to absorb the compound, washed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile, and the like, and isolated by concentrating under reduced pressure followed by lyophilization. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner or as above. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N' -dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, S. M. Berge, et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66. 1-19 (1977)). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. Preferably, a compound of Formula I can be converted to a base salt by treating with an aqueous solution of the desired base, such that the resulting pH is greater than 9.

The solution can be passed through a C18 cartridge to absorb the compound, washed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile and the like, and isolated by concentrating under reduced pressure followed by lyophilization. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner or as above. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof.

The PFT inhibitory activity of compounds of Formula I was assayed in 30 mM potassium phosphate buffer, pH 7.4, containing 7 mM DTT, 1.2 mM MgCl2, 0.1 mM leupeptin, 0.1 mM pepstatin, and 0.2 mM phenylmethylsulfonyl fluoride. Assays were performed in 96 well plates (Wallec) and employed solutions composed of varying concentrations of a compound of Formula I in 100% DMSO. Upon addition of both substrates, radiolabeled farnesyl pyrophosphate ( [1-3H] , specific activity 15-30 Ci/mmol, final concentration 0.12 μM) and (biotinyl) -Ahe-Tyr-Lys-Cys- Val-Ile-Met peptide (final concentration 0.1 μM) , the enzyme reaction was started by addition of 40-fold purified rat brain farnesyl protein transferase. After incubation at 37°C for 30 minutes, the reaction was terminated by diluting the reaction 2.5-fold with a stop buffer containing 1.5 M magnesium acetate, 0.2 M H3P04, 0.5% BSA, and strepavidin beads (Amersham) at a concentration of 1.3 mg/mL. After allowing the plate to settle for 30 minutes at room temperature, radioactivity was quantitated on a microBeta counter (model 1450, Wallec) .

As shown below in Table I, compounds of Formula I show IC50 values of 0.5 to 1000 nM in the assay discussed above and are thus valuable inhibitors of protein*,farnesyl transferase enzyme which may be used in the medical treatment of tissue proliferative diseases, including cancer and restenosis.

TABLE I

Peptide IC50 (μl

Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-DAla-CONH2 0 . 017 Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-DAla-CONHEt 0 . 230 Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-DAla-CONHNH2 0 . 062 Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-DAla-C02Me 0 , . 019 Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-DAla-COOH 0 , . 048 Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-Ala-NH2 0 . . 015 Cbz-His-Tyr-Ser(OBn) -Trp-DAla-NH2 0 . . 040 Cbz-His-Tyr(OB ) -Ser-Trp-DAla- H2 1 . . 8 Cbz-His-Phe-Ser(OBn) -Trp-DAla-NH2 0 . . 010 Cbz-His-Tyr(OBn) -Ser(OBn) -Ala-DAla-NH2 0 . . 33 Cbz-DHis-Tyr(OBn) -Ser(OBn) -Trp-DAla-NH2 0 . . 12 Cbz-His-DTyr(OBn) -Ser(OBn) -Trp-DAla-NH2 0 . , 039 Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-C02Me 0 . , 115 Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-NH2 0 . 083 Cbz-His-Tyr(OBn) -Ser(OBn) -DAla-C02Me 0 . , 142 Cbz-His-Tyr(OBn) -Ser(OBn) -DAla-COOH 0 . 404 Cbz-His-Tyr(OBn) -Cys-Trp-DAla-NH2 0 . 004 Cbz-His-Tyr(OPQ3H2) -Ser(OBn) -Trp-DAla-NH2 0 . 009

The compounds of the present invention can be prepared and administered in a wide variety of oral, rectal, and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I. For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from 5 or 10 to about 70 percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration. For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use as inhibitors of PFT, the compounds utilized in the pharmaceutical methods of this invention are administered at the initial dosage of about 0.01 mg/kg to about 20 mg/kg daily. A daily dose range of about 0.01 mg/kg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention. For added clarity, complex chemical names describing compounds of Formula I are followed by structural abbreviations, which are shown in braces, wherein the structural elements are as defined in the Table of Abbreviations above.

EXAMPLE 1 N- fN- ΓN- IN- f (Phenylmethoxy)carbonyll -L-histidyll -0- (phenylmethyl) -L-tvrosvll -0- (phenvl ethvl) -L-servll -p- alanine. methvl ester -fCbz-His-Tvr(OBn) -Ser(OBn) -D-Ala- CO-Me ) Step 1: Boc-Ser(OBn) -D-Ala-CO^Me

To a solution of Boc-Ser(OBn) (4.12 g, 13.95 mmol) in EtOAc (100 mL) at 0*C was added HOBT (2.35 g, 15.35 mmol) and DCC (3.17 g, 15.35 mmol). D-Alanine methyl ester hydrochloride (1.95 g, 13.95 mmol) was added followed by Et3N (2.14 mL, 15.35 mmol). The mixture was allowed to warm to room temperature and stirred overnight. The mixture was filtered, and the filtrate was washed with saturated aqueous NaHC03, brine, dried (MgS04) , and concentrated. Flash chromatography (40% EtOAc/hexane) gave 2.60 g of the title compound as a colorless oil; CI-MS 381 (m+1) .

Step 2: Ser(OBn) -D-Ala-CO=Me*TFA To a solution of Boc-Ser(OBn) -D-Ala-C02Me from

Step 1 above (2.44 g, 6.41 mmol) in CH2C12 (10 mL) was added TFA (3 mL) . The solution was stirred for 6 hours at room temperature, then concentrated. The residue was taken up in CH2C12 and reconcentrated. After trituration with ether, the title compound was obtained as a white solid, mp 109-110°C.

Step 3: Boc-Tyr(OBn) -Ser(OBn) -D-Ala-CQ=Me

To a solution of Boc-Tyr(OBn) (0.94 g, 2.54 mmol) in DMF (10 mL) at 0°C was added HOBT (0.47 g,

3.04 mmol) and DCC (0.63 g, 3.04 mmol). Ser(OBn) -D- Ala-C02Me*TFA from Step 2 above (1.0 g, 2.54 mmol) was added followed by Et3N (0.42 mL, 3.04 mmol). The mixture was allowed to warm to room temperature and stirred overnight. The mixture was filtered, and the filtrate was diluted with CHC13, washed twice with saturated aqueous NaHC03, brine, dried (MgS04) , and concentrated. Flash chromatography (50% EtOAc/hexane) gave 1.35 g of the title compound as a white solid, mp 132-133°C; CI-MS 634 (m+1). Step 4: Tyr(OBn) -Ser(OBn) -D-Ala-CO.Me-TFA

Prepared according to Step 2 above, substituting Boc-Tyr(OBn) -Ser(OBn) -D-Ala-C02Me for Boc-Ser(OBn) -D- Ala-C02Me. The title compound was obtained as a white solid; CI-MS 534 (m+1) .

Step 5: Cbz-His-Tyr(OBn) -Ser(OBn) -D-Ala-CQ2Me

Prepared according to Step 3 above, by substituting Cbz-His for Boc-Tyr(OBn) and Tyr(OBn)- Ser(OBn) -D-Ala-C02Me*TFA for Ser(OBn) -D-Ala-C02Me*TFA. The title compound was obtained as a white solid, mp 188-191°C. Anal. Calc. for C44H48N609*H20:

C, 64.22; H, 6.12; N, 10.21; Found: C, 64.15; H, 5.99; N, 10.17.

EXAMPLE 2 N- TN- fN- fN- r (Phenylmethoxy)carbonyll -L-histidyll -O- (phenylmethyl) -L-tyrosyll -0- (phenylmethyl) -L-seryll -D- alanine. monohydrochloride {Cbz-His-Tyr(OBn) -Ser(OBn) - D-Ala*HCl)

To a suspension of Cbz-His-Tyr(OBn) -Ser(OBn) -D- Ala-C02Me from Example 1 above (0.43 g, 0.53 mmol) in THF (10 mL) and MeOH (3 mL) at 0°C was added 0.1N LiOH (5.9 mL) . The mixture was stirred for 6 hours at 0*C and then concentrated. Water was added and the pH was adjusted to 4-5 by the addition of IN HCl. The mixture was filtered, and the precipitate was collected and dried to afford 0.37 g of the title compound as a white solid, mp 190-197°C; FAB-MS 791 (m+1) . EXAMPLE 3 N- TN- TN- TN- r(Phenvlmethoxv)carbonvll -L-hiatidvll -O- ( henylmethyl) -L-tvrosvll -O- (phenvlmethvli -L-seryll -L- tryptophan. methvl ester (Cbz-His-Tvr(OBn) -Ser(OBn) -

Figure imgf000033_0001

Step 1: Boc-Tvr(OBn) -Ser(OBn) -CO.Me

To a solution of Boc-Tyr(OBn) (1.88 g, 6.50 mmol) in EtOAc (30 mL) at 0*C was added HOBT hydrate (1.19 g, 7.80 mmol) followed by DCC (1.61 g, 7.80 mmol). A solution of Ser(OBn) -C02Me*TFA (2.1 g, 6.50 mmol) in EtOAc (20 mL) was added followed by Et3N (1.09 mL, 7.80 mmol) . The mixture was allowed to warm to room temperature and stirred overnight. The mixture was filtered, diluted with EtOAc, and washed twice with saturated aqueous NaHC03, brine, dried over MgS04, and concentrated. Flash chromatography (40% EtOAc/hexane) gave 2.67 g (73%) of the title compound as a white solid, mp 81-84°C.

Step 2: Boc-Tyr(OBn) -Ser(OBn)

Prepared according to Example 2, by substituting

Boc-Tyr(OBn) -Ser(OBn) -C02Me for Cbz-His-Tyr(OBn) -

Ser(OBn) -D-Ala-C02Me. The title compound was obtained as a white foam.

Step 3: Boc-Tyr(OBn) -Ser(OBn) -Trp-CQ2Me

Prepared according to Example l, Step 3, by substituting Boc-Tyr(OBn) -Ser(OBn) for Boc-Tyr(OBn) and

Trp-C02Me*HCl for Ser(OBn) -D-Ala-C02Me*TFA. The title compound was obtained as a white foam; FAB-MS 750

(m+1) .

Step 4: Tyr(OBn) -Ser(OBn) -Trp-CO^MeTFA

Prepared according to Example 1, Step 2, by substituting Boc-Tyr(OBn) -Ser(OBn) -Trp-C02Me for Boc-

Ser(OBn) -D-Ala-C02Me, and adding 2 equiv of thioanisole in addition to TFA. The title compound was obtained as white solid.

Step 5: Cbz-His-Tvr(OBn) -Ser(OBn) -Trp-CO.Me Prepared according to Example 1, Step 5, by substituting Tyr(OBn) -Ser(OBn) -Trp-C02Me*TFA for Tyr(OBn) -Ser(OBn) -D-Ala-C02Me*TFA. The title compound was obtained as a white foam; FAB-MS 920 (m+1) .

EXAMPLE 4

Nα- fN- fN- fN- TN- f (Phenylmethoxv)carbonyl! -L-histidyll -O- (phenvlmethyl) -L-tvrosvll -O- (phenylmethyl) -L-seryll -L- trvptophvll -D-alaninamide -fCbz-His-Tvr(OBn) -Ser(OBn) - Trp-D-Ala-CONH ) Using an ABI model 431A solid phase peptide synthesizer, Fmoc-NH-Rink resin (0.25 mMol scale) was treated with 20% piperidine in NMP to afford NH2-Rink resin. Sequential coupling of Fmoc-protected D-Ala, Trp, Ser(OBn) and Tyr(OBn) (DCC and HOBT in NMP) and Fmoc deprotection (20% piperidine in NMP) reactions were run using a fourfold excess of reagents in the coupling steps and traditional resin washing cycles to afford Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH-Rink resin. This tetrapeptide resin was transferred to an uninstrumented reaction vessel and treated with a fourfold excess of Cbz-His, DCC and HOBT in DMF, shaking overnight at room temperature. After removal of excess reagents, the resulting substituted pentapeptide was cleaved from the resin by treatment with 50% TFA in DCM at room temperature for 2.5 hours. Evaporation of solvents, lyophilization and purification by reversed phase chromatography (C18-column, eluted with a 20-70% gradient of MeCN in water (both solvents acidified with 0.1% TFA)) afforded Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH2 as its TFA salt upon lyophilization. FAB-MS: 976 (m+1) . Using analogous methods the following most preferred compounds of Formula I with carboxamides at the C-terminus may be prepared:

Cbz-His-Tyr (OBn) -Ser(OBn) -Trp-Ala-CONH2, ES-MS 976 (m+1);

Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-Gly-CONH2;

Cbz-His-Tyr-Ser(OBn) -Trp-D-Ala-CONH2, FAB-MS 886 (m+1) ;

Cbz-His-D-Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH2, FAB- MS 976 (m+1) ;

Cbz-His-Phe-Ser(OBn) -Trp-D-Ala-CONH2, ES-MS 870 (m+1) ;

Cbz-His-Tyr (OBn) -Ser-Trp-D-Ala-CONH2, FAB-MS 886 (m+1) ; Cbz-D-His-Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH2, FAB-

MS 976 (m+1) ;

Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-CONH2, ES-MS 905 (m+1) ;

Cbz-His-Tyr (OBn) -Ser(OBn) -Ala-D-Ala-CONH2, ES-MS 861 (m+1) ;

Cbz-His-Phe-Ser(OBn)-Trp-Ala-CONH2; ES-MS 870 (m+1) ;

BnNHCO-His-Tyr(OBn) -Ser(OBn) -Trp-Gly-CONH2;

BnNHCO-His-Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH2; BnNHCO-His-Tyr(OBn) -Ser(OBn) -Trp-Ala-CONH2;

Cbz-His-Tyr(OP03H2) -Ser(OBn) -Trp-DAla-CONH2, ES-MS 966 (m+1) ;

Cbz-His-p(CH2P03H2)Phe-Ser(OBn) -Trp-DAla-CONH2;

Cbz-His-p(CH2P03Et2)Phe-Ser(OBn) -Trp-DAla-CONH2, ES-MS 1021 (m+1) ;

Cbz-His-p(CF2P03H2)Phe-Ser(OBn) -Trp-DAla-CONH2;

Cbz-His-Glu-Ser(OBn) -Trp-DAla-CONH2, ES-MS 852.3 (m+1) ;

Cbz-His-Asp-Ser(OBn) -Trp-DAla-CONH2, ES-MS 838.6 (m+1) ; Cbz-His-Tyr(OBn) -Ser(OP03H2) -Trp-DAla-CONH2, FAB-MS 966.2 (m+1); and

Cbz-His-Tyr(OP03H2) -Ser(OBn) -Trp-CONH2, ES-MS 895.5 (m+1) .

EXAMPLE 5 Ng- fN- fN- fN- fN- f (Phenylmethoxv)carbonyl! -L-histidyll -0- ( henylmethyl) -L-tvrosvll -L-cvsteinvl-L-tryptophyl! -D- alaninamide (Cbz-His-Tvr(OBn) -Cvs-Trp-D-Ala-CONH.,} Sequential coupling and deprotection of Fmoc- protected D-Ala, Trp, Cys(STr) , Tyr(OBn) and Cbz-His by the solid phase method described in Example 4, followed by treatment with 60% TFA in DCM for 3.5 hours at room temperature gave crude Cbz-His-Tyr(OBn) -Cys-Trp-D-Ala- CONH2 upon evaporation of solvents and lyophilization. Purification was accomplished by reversed phase chromatography on a C18 column, eluted with a 25 to 75% gradient of MeCN in water (both solvents acidified with 0.1% TFA) to give the TFA salt of the title compound upon lyophilization. ES-MS: 902 (m+1).

Using analogous methods the following most preferred compounds of Formula I which contain Cys and a carboxamide at the C-terminus may be prepared: Cbz-His-Tyr(OBn) -Cys-Trp-Ala-CONH2; Cbz-His-Tyr(OBn) -Cys-Trp-Gly-CONH2;

BnNHCO-His-Tyr(OBn) -Cys-Trp-D-Ala-CONH2; BnNHCO-His-Tyr(OBn) -Cys-Trp-Ala-CONH2; BnNHCO-His-Tyr(OBn) -Cys-Trp-Gly-CONH2; Cbz-Cys-Tyr(OBn) -Ser(OBn) -Trp-DAla-CONH2, FAB-MS 942.6 (m+1); and

Cbz-His-Tyr(OP03H2) -Cys-Trp-DAla-CONH2.

The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Warner-Lambert Company

(11) TITLE OF INVENTION: Substituted Tetra- and Pentapeptide Inhibitors of Protein: Farnesyl Transferase

(iii) NUMBER OF SEQUENCES: 59

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Warner-Lambert Company

(B) STREET: 2800 Plymouth Rd.

(C) CITY: Ann Arbor

(D) STATE: MI

(E) COUNTRY: US

(F) ZIP: 48105

(V) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: Patentin Release 1.0,Ver. 1.25

(Vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Crissey, Todd

(B) REGISTRATION NUMBER: 37807

(C) REFERENCE/DOCKET NUMBER: PD-4631PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 313 996-7530

(B) TELEFAX: 313 996-1553 (2) INFORMATION FOR SEQ ID NO:l:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:

Cys Xaa Xaa Xaa

1

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Cys Xaa Xaa Xaa

1

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Cys Xaa Xaa Xaa

1 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Cys Xaa Xaa Xaa

1

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

His Xaa Xaa Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

His Xaa Xaa Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

His Xaa Xaa Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

His Xaa Xaa Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

His Xaa Xaa Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

His Xaa Xaa Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

His Xaa Xaa Trp Gly

1 5

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

His Xaa Xaa Trp Gly

1 5 (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13

His Xaa Xaa Trp Gly

1 5

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

His Xaa Xaa Trp Gly

1 5

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

His Xaa Xaa Trp Gly 1 5 (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16

His Xaa Xaa Trp Gly 1 5

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 .amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17.

His Phe Xaa Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

His Xaa Xaa Trp

1 (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19

His Xaa Xaa Trp

1

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

His Xaa Cys Trp

1

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: .amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

His Xaa Cys Trp

1 (2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22

His Xaa Xaa Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

His Xaa Xaa Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

His Xaa Xaa Trp Ala

1 5 (2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

His Xaa Xaa Trp Ala 1 5

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

His Xaa Xaa Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

His Xaa Xaa Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28

His Xaa Xaa Trp Gly

1 5

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

His Xaa Xaa Trp Gly

1 5

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

His Xaa Xaa Trp Gly

1 5 (2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31

His Xaa Xaa Trp Gly

1 5

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

His Xaa Xaa Trp Gly

1 5

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

His Xaa Xaa Trp Gly

1 5 (2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34

His Xaa Cys Trp Ala 1 5

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

His Xaa Cys Trp Ala 1 5

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

His Xaa Cys Trp Ala

1 5 (2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

His Xaa Cys Trp Ala 1 5

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 .amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

His Xaa Cys Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

His Xaa Cys Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 0:

His Xaa Cys Trp Gly 1 5

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

His Xaa Cys Trp Gly 1 5

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

His Xaa Cys Trp Gly 1 5 (2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43

His Xaa Cys Trp Gly 1 5

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

His Xaa Cys Trp Gly

1 5

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

His Xaa Cys Trp Gly 1 5 (2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

His Xaa Cys Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

His Xaa Cys Trp Ala

1 5

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

His Xaa Cys Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49

His Xaa Cys Trp Ala 1 5

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: .amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

His Xaa Cys Trp Ala 1 5

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

His Xaa Cys Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52;

His Xaa Cys Trp Gly 1 5

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

His Xaa Cys Trp Gly 1 5

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

His Xaa Cys Trp Gly

1 5 (2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55

His Xaa Cys Trp Gly 1 5

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

His Xaa Cys Trp Gly

1 5

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

His Xaa Cys Trp Gly 1 5 (2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58

His Xaa Xaa Trp

1

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Tyr Lys Cys Val lie Met 1 5

Claims

What is claimed is:CLAIMS
A compound of the Formula I
Figure imgf000059_0001
n - 1 or 2;
A = -COR2, -C02R2, -CONHR2, -CSR2, -C(S)R2,
-C(S)NHR2, or H; wherein R2 is alkyl, - (CH2)m-cycloalkyl,
- (CH2)m-aryl, - (CH2)m-heteroaryl, and m ■ 0, 1,
2, or 3;
R = independently H or Me;
Y = independently H or Me;
Z = independently H or Me;
Figure imgf000059_0002
wherein R4' » H or Me;
-SR4", wherein R4" » H, alkyl, trityl, or heteroaryl;
Figure imgf000059_0003
wherein R5' - H, -OH, -0-alkyl, alkyl, -CO- ryl, - (CH2)m-aryl, -0(CH2)m-cycloalkyl, -0(CH2)m-aryl, -0(CH2)m-heteroaryl, -0P03Rs"2, -CH2P03R5"2,
-CF2P03R5"2, or -CFHP03R5"2, wherein R5' is located at either the ortho, meta, or para position and R5" - H, alkyl, alkylaryl, or cyclohexyl, and m is as described above; -COOR7, wherein R7 « H, Me, t-butyl, or benzyl; -SR8, wherein R8 » H or trityl; R6 - -OR6', wherein R6' - H, benzyl, -P03R5"2, wherein Rs" is as described above;
-CH2-R9, wherein R9 - -P03R5 " 2 , wherein R5'' is as described above;
-SR6", wherein R6" - H, benzyl, or trityl; C - Gly, Ala, Val, Leu, He, Phe, Tyr, Tyr(OMe) ,
Pgl, homoPhe, Trp, Trp(Me) , or Trp(CHO); D - Gly, Ala, or absent;
E = -COOH, -CONH2, -C0NHNH2, -CONHR10, or -C02R10, wherein R10 - H, alkyl, - (CH2)m-cycloalkyl, - (CH2)m-aryl, or - (CH2)m-heteroaryl, and m is as described above; an isomer or a pharmaceutically acceptable salt thereof.
A compound according to Claim 1 which is a compound of Formula II:
Figure imgf000060_0001
wherein n' = 1 or 2;
A' ■= -COR2', -C02R2', or -CONHR2', wherein R2' = alkyl, - (CH2)m-aryl, - (CH2)m- heteroaryl, and m = 0, 1, or 2; R = independently H or Me; Y = independently H or Me; Z - independently H or Me R12'
R12 -
wherein R12' « H or Me;
-SR12", wherein R12" - H or alkyl;
Figure imgf000061_0001
wherein R13' - H, -OH, -O-alkyl, alkyl, -CO-aryl, benzyl, -O-benzyl, wherein R13 is located at either the ortho, meta, or para position;
-OP03R14 2, -CH2P03R14 2, or -CF2P03R14 2, wherein
R14 •= H or alkyl;
-COOR15, wherein R15 ■ H, Me, t-butyl, or benzyl;
R16 = -OR16', wherein R16' = H, benzyl, -P03R14 2, wherein R14 is as described above;
-CH2-R16", wherein R16" - -P03R14 2, wherein R14 is as described above; -SR16'", wherein R16'" = H or benzyl;
C = Ala, Trp, Trp(Me), or Trp(CHO); D' ■= Gly, Ala, absent;
E' -= -COOMe, -CONH2, -CONHNH2, -COOH, or -CONH- alkyl; an isomer or a pharmaceutically acceptable salt thereof.
3. A compound according to Claim l wherein A is Cbz, BnNHCO, R is H and n is 1 or 2.
4. A compound according to Claim 1 wherein R4 is
H
|) , -SH and Y is H.
5. A compound according to Claim 1 wherein R5 is
Figure imgf000062_0001
wherein R5' - H, -OH, -OBn, -OP03H2, -CH2P03H2,
-CH2P03Et2, -CF2P03H2, or wherein R5 - -COOH, and Z is H.
6. A compound according to Claim 1 wherein R6 is -OBn, -OH, -SH, or -OP03H2.
7. A compound according to Claim 1 wherein C is Trp or Ala.
8. A compound according to Claim 1 wherein D is Gly, Ala, or absent.
9. A compound according to Claim 1 wherein E is -COOH, -CONH2, -COOMe, -CONHEt, -C0NHNH2, or -CONHMe.
10. A compound according to Claim 1 which is
Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH2,•
Cbz-Cys-Tyr(OBn) -Ser(OBn) -Trp-DAla-CONH2;
Cbz-His-Tyr(OP03H2) -Ser(OBn) -Trp-DAla-CONH2; Cbz-His-p(CH2P03H2)Phe-Ser(OBn) -Trp-DAla-
CONH2;
Cbz-His-p(CH2P03Et2)Phe-Ser(OBn) -Trp-DAla-
CONH2;
Cbz-His-p(CF2P03H2)Phe-Ser(OBn) -Trp-DAla- CONH2;
Cbz-His-Glu-Ser(OBn) -Trp-DAla-CONH2;
Cbz-His-Asp-Ser(OBn) -Trp-DAla-CONH2;
Cbz-His-Tyr(OBn) -Ser(OP03H2) -Trp-DAla-CONH2;
Cbz-His-Tyr(OP03H2) -Cys-Trp-DAla-CONH2; and Cbz-His-Tyr(OP03H2) -Ser(OBn) -Trp-CONH2.
11. A compound according to Claim l selected from the group consisting of:
Cbz-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala-CONHMe;
Cbz-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala-CONHEt; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala-CONHNH2;
Cbz-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala-C02Me; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Ala-CONH2; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Ala-CONHMe; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Ala-CONHEt;
Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Ala-CONHNH2; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Ala-C02Me; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Ala; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Gly-CONH2; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Gly-CONHMe;
Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Gly-CONHEt; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Gly-CONHNH2; Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Gly-C02Me; and Cbz-His-Tyr(OBn -Ser(OBn) -Trp-Gly.
12. A compound according to Claim 1 selected from the group consisting of:
Cbz-His-Tyr-Ser(OBn) -Trp-D-Ala-CONH2; Cbz-His-Tyr(OBn) -Ser-Trp-D-Ala-CONH2; Cbz-His-Phe-Ser(OBn) -Trp-D-Ala-CONH2; Cbz-His-Phe-Ser(OBn) -Trp-Ala-CONH2; Cbz-His-Tyr(OBn) -Ser(OBn) -Ala-D-Ala-CONH2; Cbz-D-His-Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH2; and
Cbz-His-D-Tyr(OBn) -Ser(OBn) -Trp-D-Ala-CONH:
13. A compound according to Claim 1 selected from the group consisting of:
Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-C02Me; Cbz-His-Tyr(OBn) -Ser(OBn) -Trp-CONH2; Cbz-His-Tyr(OBn) -Ser(OBn) -D-Ala-C02Me; Cbz-His-Tyr(OBn) -Ser(OBn) -D-Ala; Cbz-D-His-Tyr(OBn) -Ser(OBn) -Trp-C02Me; Cbz-His-D-Tyr(OBn) -Ser(OBn) -Trp-C02Me; Cbz-His-Tyr(OBn) -Cys-Trp-CONH2; and BnNHCO-His-Tyr(OBn) -Cys-Trp-CONH2.
14. A compound according to Claim 1 selected from the group consisting of:
BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala-CONH2; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala- CONHMe;
BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala- CONHEt;
BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala- CONHNH2; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala-C02Me;
BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-D-Ala; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Ala-CONH2; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Ala-CONHMe; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Ala-CONHEt; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Ala-CONHNH2;
BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Ala-C02Me; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Ala; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Gly-CONH2; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Gly-CONHMe; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Gly-CONHEt;
BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Gly-CONHNH2; BnNHCO-His-Tyr(OBn -Ser(OBn) -Trp-Gly-C02Me; and
BnNHCO-His-Tyr(OBn) -Ser(OBn) -Trp-Gly.
15. A compound according to claim 1 selected from the group consisting of:
Cbz-His-Tyr(OBn) -Cys-Trp-D-Ala-CONH2,* Cbz-His-Tyr(OBn) -Cys-Trp-D-Ala-CONHMe; Cbz-His-Tyr(OBn) -Cys-Trp-D-Ala-CONHEt; Cbz -His Tyr(OBn) Cys-Trp-D-Ala-CONHNH2; Cbz -His Tyr(OBn) Cys-Trp -D-Ala-C02Me; Cbz -His Tyr (OBn) Cys-Trp -D-Ala; Cbz -His Tyr(OBn) Cys-Trp Ala-CONH2; Cbz -His Tyr(OBn) Cys-Trp Ala-CONHMe; Cbz -His Tyr(OBn) Cys-Trp -Ala-CONHEt; Cbz -His Tyr(OBn) Cys-Trp Ala-CONHNH2; Cbz -His Tyr(OBn) Cys-Trp Ala-C02Me; Cbz His Tyr(OBn) Cys-Trp -Ala; Cbz -His Tyr (OBn) Cys-Trp Gly-CONH2; Cbz His Tyr(OBn) Cys-Trp Gly-CONHMe; Cbz -His Tyr (OBn) Cys-Trp Gly-CONHEt; Cbz His Tyr (OBn) Cys-Trp Gly-CONHNH2; Cbz His Tyr (OBn) Cys-Trp Gly-C02Me; and Cbz •His Tyr (OBn) Cys-Trp* Gly.
16. A compound according to Claim l selected from the group consisting of:
BnNHCO-His-Tyr(OBn -Cys-Trp -D-Ala-CONH2;
BnNHCO-His-Tyr(OBn -Cys-Trp D-Ala-CONHMe; BnNHCO-His-Tyr(OBn -Cys-Trp D-Ala-CONHEt;
BnNHCO-His-Tyr(OBn -Cys-Trp D-Ala-CONHNH2; BnNHCO-His-Tyr(OBn -Cys-Trp D-Ala-C02Me; BnNHCO-His-Tyr(OBn Cys-Trp D-Ala; BnNHCO-His-Tyr(OBn Cys-Trp Ala-CONH2; BnNHCO-His-Tyr(OBn Cys-Trp Ala-CONHMe;
BnNHCO-His-Tyr(OBn -Cys-Trp Ala-CONHEt; BnNHCO-His-Tyr(OBn -Cys-Trp Ala-CONHNH2; BnNHCO-His-Tyr(OBn Cys-Trp Ala-C02Me; BnNHCO-His-Tyr(OBn Cys-Trp -Ala; BnNHCO-His-Tyr(OBn Cys-Trp Gly-CONH2;
BnNHCO-His-Tyr(OBn Cys-Trp Gly-CONHMe,* BnNHCO-His-Tyr(OBn Cys-Trp Gly-CONHEt; BnNHCO-His-Tyr(OBn Cys-Trp Gly-CONHNH2; BnNHCO-His-Tyr(OBn Cys-Trp Gly-C02Me; and BnNHCO-His-Tyr(OBn •Cys-Trp Gly.
17. A method of treating tissue proliferative diseases comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
18. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
19. A method of treating cancer comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
20. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 2 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
21. A method of treating restenosis comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
22. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 10 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
23. A process for the preparation of compounds of Formula I according to Claim 1, or a pharmaceutically acceptable salt thereof, comprising the steps of employing solid phase support technology and sequentially coupling peptide building blocks by utilizing a solid phase peptide synthesizer, cleaving coupled building blocks from the solid phase support and optionally modifying the C-terminal of the coupled building blocks in solution phase to afford a compound of Formula I or a pharmaceutically acceptable salt thereof.
24. A process for the preparation of compounds of Formula I according to Claim 1, or a pharmaceutically acceptable salt thereof, comprising the steps of employing solution phase technology and sequentially coupling peptide building blocks to afford a compound of Formula I or a pharmaceutically acceptable salt thereof.
PCT/US1995/014010 1994-12-09 1995-10-27 Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase WO1996017861A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US35347394A true 1994-12-09 1994-12-09
US08/353,473 1994-12-09

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP51758095A JPH10510261A (en) 1994-12-09 1995-10-27 Protein: farnesyltransferase substituted tetra- and pentapeptides inhibitors
AU39712/95A AU3971295A (en) 1994-12-09 1995-10-27 Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
MX9703208A MX9703208A (en) 1994-12-09 1995-10-27 Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase.

Publications (1)

Publication Number Publication Date
WO1996017861A1 true WO1996017861A1 (en) 1996-06-13

Family

ID=23389273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014010 WO1996017861A1 (en) 1994-12-09 1995-10-27 Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Country Status (5)

Country Link
JP (1) JPH10510261A (en)
AU (1) AU3971295A (en)
CA (1) CA2204144A1 (en)
MX (1) MX9703208A (en)
WO (1) WO1996017861A1 (en)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
WO2007093827A1 (en) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
WO2008144062A1 (en) 2007-05-21 2008-11-27 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US7553854B2 (en) 2006-04-19 2009-06-30 Novartis Vaccines And Diagnostics, Inc. 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2336120A1 (en) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2016020864A1 (en) 2014-08-06 2016-02-11 Novartis Ag Protein kinase c inhibitors and methods of their use
US9266824B2 (en) 2014-01-13 2016-02-23 Warsaw Orthopedic, Inc. Methods and compositions for making an amino acid triisocyanate
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2018058022A1 (en) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10144730B2 (en) 2011-11-17 2018-12-04 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528486A2 (en) * 1991-08-16 1993-02-24 Merck & Co., Inc. Non-substrate inhibitors of farnesyl protein transferase
WO1995011917A1 (en) * 1993-10-25 1995-05-04 Parke, Davis & Company Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528486A2 (en) * 1991-08-16 1993-02-24 Merck & Co., Inc. Non-substrate inhibitors of farnesyl protein transferase
WO1995011917A1 (en) * 1993-10-25 1995-05-04 Parke, Davis & Company Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEBOLT-LEOPOLD ET AL: "inhibition of ras farnesyltransferase...", PROC.AM.ASS.CANCER RES., vol. 35(0), pages 593 *
W.M.KAST ET AL: "Eradication of adenovirus e1-induced tumors by e1a-specific cytotoxic t lymphocytes", CELL, vol. 59, 17 November 1989 (1989-11-17), pages 603 - 614 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
WO2007093827A1 (en) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
US8173689B2 (en) 2006-04-19 2012-05-08 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US8710048B2 (en) 2006-04-19 2014-04-29 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US7553854B2 (en) 2006-04-19 2009-06-30 Novartis Vaccines And Diagnostics, Inc. 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2336120A1 (en) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2805945A1 (en) 2007-01-10 2014-11-26 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
WO2008144062A1 (en) 2007-05-21 2008-11-27 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
EP3103791A1 (en) 2007-06-27 2016-12-14 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US9505784B2 (en) 2009-06-12 2016-11-29 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US10144730B2 (en) 2011-11-17 2018-12-04 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US9266824B2 (en) 2014-01-13 2016-02-23 Warsaw Orthopedic, Inc. Methods and compositions for making an amino acid triisocyanate
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2016020864A1 (en) 2014-08-06 2016-02-11 Novartis Ag Protein kinase c inhibitors and methods of their use
WO2018058022A1 (en) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies

Also Published As

Publication number Publication date
CA2204144A1 (en) 1996-06-13
AU3971295A (en) 1996-06-26
JPH10510261A (en) 1998-10-06
MX9703208A (en) 1997-07-31

Similar Documents

Publication Publication Date Title
US5192746A (en) Cyclic cell adhesion modulation compounds
Barlos et al. Efficient" one-pot" synthesis of N-tritylamino acids
EP0406428B1 (en) Peptide derivatives and their use
CA2091873C (en) Parathyroid hormone derivatives
CA2027936C (en) Cyclic anti-aggregatory peptides
AU633872B2 (en) Glycine derivatives
CA1241643A (en) Peptides affecting the immune regulation and a process for their preparation
CA1311583C (en) Peptide derivatives and their application, in particular in therapy
US6075121A (en) Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
CA1245217A (en) Renin inhibitory peptides having phe su13 xx deletion
FI120494B (en) Factor Xa inhibitors
JP2755351B2 (en) Anti - aggregated peptide
US6534495B1 (en) Serine protease inhibitors
EP0276436B1 (en) Phosphinic acid derivatives
JP3494649B2 (en) Endothelin antagonists
AU639409B2 (en) Conformationally stabilized cell adhesion peptides
CA2338524C (en) Inhibitors of urokinase and blood vessel formation
US4148788A (en) Synthesis of thymosin α1
US4086221A (en) Polypeptides and process for producing the same
US4024248A (en) Peptides having LH-RH/FSH-RH activity
US5446130A (en) Parathyroid hormone antagonists
US6255285B1 (en) Phenethylamine derivatives
KR910003619B1 (en) Peptide boronic acid innibitors of trypsin like proteases
EP0260118B1 (en) Selective amidination of diamines
JP3509029B2 (en) Bioactive cyclized polypeptide

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BG BY CA CN CZ EE FI GE HU JP KG KR KZ LT LV MD MX NO NZ PL RO RU SG SI SK TJ UA UZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/003208

Country of ref document: MX

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2204144

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2204144

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 296020

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1019970703844

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1995937675

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995937675

Country of ref document: EP

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 1019970703844

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019970703844

Country of ref document: KR